OUP user menu

The Expression of Myeloid Antigens CD13 and/or CD33 Is a Marker of ALK+ Anaplastic Large Cell Lymphomas

Ian M. Bovio MD, Robert W. Allan MD
DOI: http://dx.doi.org/10.1309/PLN1NA4QB2PC1CMQ 628-634 First published online: 1 October 2008

Abstract

We retrospectively studied the immunophenotype by flow cytometry of 20 anaplastic large cell lymphomas (ALCLs) (9 anaplastic lymphoma kinase [ALK]+ and 11 ALK–) with a particular emphasis on the aberrant expression of the myeloid associated antigens CD13 and/or CD33. All ALCLs expressed CD45, HLA-DR, and CD30. Most (8/9) ALK+ ALCLs expressed at least 1 surface T-cell antigen (CD4, 6/9 [67%]; CD7, 6/9 [67%]; CD2, 5/9 [56%]; CD5, 2/9 [22%]; CD8, 2/9 [22%]; CD3, 1/9 [11%]). All ALK– ALCLs expressed at least 1 surface T-cell antigen (CD3, 7/11 [64%]; CD4, 6/11 [55%]; CD2, 6/11 [55%]; CD7, 2/11 [18%]; CD5, 1/11 [9%]; CD8, 1/11 [9%]). CD13 and/ or CD33 were expressed in all (9/9) ALK+ ALCLs compared with 1 of 11 ALK– ALCLs (9%) (P < .0001). Surface CD3 was more likely expressed in ALK– ALCLs (7/11) compared with ALK+ ALCLs (1/9) (P = .03). The myeloid-associated antigens CD13 and/ or CD33 are sensitive but not entirely specific markers of ALK+ ALCLs and should not be misinterpreted as indicating myeloid sarcoma.

Key Words:
  • Anaplastic large cell lymphoma
  • ALK-1
  • Flow cytometry
  • Anaplastic lymphoma kinase